葛兰素史克Glaxosmithkline（GSK）2025年第四季度及全年产品线资产及临床试验报告「LSE」（英文版）（67页）.pdf

1、Pipeline assets and clinical trials appendixQ4 2025Infectious disease2ContentsInnovation:Pipeline growthClinical trialsRespiratory,Immunology and Inflammation(RI&I)OncologyHIVInfectious DiseasesInfectious disease3Innovation:Pipeline growthOverview of potential new vaccines and medicinesHIVHIVOncolog

2、yOncologyInfectious DiseasesInfectious DiseasesGlossaryGlossaryInnovation:Pipeline growthRIIRI&IRI&IOncologyHIVInfectious DiseasesPhase III/RegistrationPhase III/Registration17Exdensur(depemokimab)Long-acting anti-IL5 antibody*Asthma*linerixibat(GSK2330672)IBAT inhibitorCholestatic pruritus in prima

3、ry biliary cholangitisNucala(mepolizumab)Anti-IL5 antibodyCOPD1camlipixant(GSK5464714)P2X3 receptor antagonistRefractory chronic coughefimosfermin alfa(GSK6519754)FGF21 analog*MASH2Low carbon version of MDI3,Ventolin(salbutamol)Beta 2 adrenergic receptor agonistAsthmaBlenrep(belantamab mafodotin)Ant

4、i-BCMA ADC*Multiple myelomaJemperli(dostarlimab)Anti-PD-1 antibody*dMMR/MSI-H colon cancer*risvutatug rezetecan(GSK5764227)ADC targeting B7-H3*ES-SCLC4*velzatinib(GSK6042981)KIT inhibitor*Gastrointestinal stromal tumoursZejula(niraparib)PARP inhibitor*Newly diagnosed glioblastoma multiformeArexvy(RS

5、V vaccine)Recombinant protein,adjuvanted*RSV adults(18-49 YoA5 AIR6)*Blujepa(gepotidacin)BTI inhibitor*Uncomplicated UTI7*tebipenem pivoxil(GSK3778712)Antibacterial carbapenem*Complicated UTI7bepirovirsen(GSK3228836)Antisense oligonucleotide*Chronic HBV8 infection*Bexsero(MenB vaccine)Recombinant pr

6、otein,OMVMeningitis B(infants US)GSK4178116Live,attenuatedVaricella new seed4*In-license or other alliance relationship with third party In registration *Additional indications or candidates also under investigation1.Chronic obstructive pulmonary disease 2.Metabolic dysfunction-associated steatohepa